Click Therapeutics Expands its Leadership with Executive and Board Appointments

“We are honored to have these industry experts on the Click team,” said David Benshoof Klein, co-founder and CEO of Click Therapeutics. “As we discover, develop and commercialize a broad pipeline of prescription digital therapeutics for the treatment of multiple medical conditions, the experience and respected tenures of Randall, Lee, and Muz solidify Click’s leadership role in digital therapeutics and in the broader digital health space.”

Joining as CFO with more than 20 years of extensive industry experience and most recently leading RBC Capital Markets’ large cap, specialty and generic pharmaceuticals team, Randall Stanicky brings the focused financial leadership necessary to expand Click’s clinical and commercial reach. Prior to RBC, Stanicky spent the majority of his Wall Street career in a similar role at Goldman Sachs. He holds a Bachelor of Commerce degree from the University of British Columbia and sits on the Board of Directors at the Children’s Tumor Foundation where he serves as an officer and chair of the audit committee. “The transformative potential of digital therapeutics and the breadth of Click’s platform is what drew me to the company,” said Stanicky. “With clear opportunities to scale the organization and improve clinical outcomes in millions of users, the executive team and I are primed to succeed with our vision.”

Lee Shapiro joins Click’s Board of Directors and will serve as chair of the audit committee. He is Managing Partner at 7wireVentures, an investment firm he co-founded over a decade ago. He recently served as Chief Financial Officer of Livongo Health until their successful $18.5B merger with Teladoc. Prior to Livongo, Mr. Shapiro was President of Allscripts from 2001 until the end of 2012. He has also served on the Board of Directors of leading health technology companies such as Medidata, ConsejoSano, Medisafe, HomeThrive and other 7wire portfolio companies. He is a member of the National Board of Directors of the American Heart Association, where he chairs the audit committee and serves on the business operations committee. He holds a J.D. from The University of Chicago Law School and a B.S. in accounting from the University of Illinois.

Dr. Muzammil Mansuri has expanded his role from Senior Strategic Advisor to Click’s Board to Chair of the Board. With over three decades of comprehensive experience in senior roles within the global biopharmaceutical industry, Dr. Mansuri’s deep knowledge of therapeutic and digital approaches to patient care is key as Click advances an industry-leading digital therapeutics pipeline. Dr. Mansuri currently serves as Partner at F-Prime Capital. Prior to joining F-Prime, Dr. Mansuri was a member of the Executive Committee at Sanofi, as Executive Vice President, Strategy, Business Development, and Licensing. Before this, he was at Gilead Sciences as Senior Vice President, Research and Development Strategy and Business Development. In that capacity he led the R&D Strategy, Business Development, and M&A activities for the company. Dr. Mansuri has served as Chief Executive Officer of several biotech companies and as a General Partner at Flagship Ventures (now Flagship Pioneering). He began his career in the pharmaceutical industry as a bench medicinal chemist with Bristol Myers. He received his B.Sc. and Ph.D. in chemistry from the University College London and conducted postdoctoral research at UCLA and Columbia University.

The executive leadership and Board announcements follow Click’s strategic partnerships with Otsuka, Boehringer Ingelheim, and a variety of payers, employers, and thought leaders.

Shapiro stated, “I have had the privilege to work with and evaluate numerous organizations seeking to advance the future of digital health. Click is uniquely positioned to seize on this moment to provide a new type of digital care. I am thrilled to join the Board to help ensure the company succeeds in this opportunity, and to become an investor in the company along with my business partner Glen Tullman.”

Board Chair Mansuri added, “Clinically validated digital therapeutics are the real solutions needed to improve patients’ health outcomes beyond what we have been able to achieve with pharmacotherapy alone. In a time when obtaining access to comprehensive care can be more difficult than ever, Click is positioned to change this paradigm.”

About Click Therapeutics

Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for patients with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program has recently entered a pivotal, fully remote, randomized, controlled trial on the Verily platform for the treatment of Major Depressive Disorder in up to 540 adults. For more information on Click, visit ClickTherapeutics.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005111/en/